Philogen SpA (STU:78Q) Debt-to-Equity : 0.08 (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Philogen SpA Debt-to-Equity?

Philogen SpA's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was €1.03 Mil. Philogen SpA's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was €10.47 Mil. Philogen SpA's Total Stockholders Equity for the quarter that ended in Dec. 2024 was €138.66 Mil. Philogen SpA's debt to equity for the quarter that ended in Dec. 2024 was 0.08.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Philogen SpA's Debt-to-Equity or its related term are showing as below:

STU:78Q' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.08 Med: 0.12 Max: 0.22
Current: 0.08

During the past 5 years, the highest Debt-to-Equity Ratio of Philogen SpA was 0.22. The lowest was 0.08. And the median was 0.12.

STU:78Q's Debt-to-Equity is ranked better than
62.99% of 1016 companies
in the Biotechnology industry
Industry Median: 0.14 vs STU:78Q: 0.08

Philogen SpA Debt-to-Equity Historical Data

The historical data trend for Philogen SpA's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Philogen SpA Debt-to-Equity Chart

Philogen SpA Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Debt-to-Equity

0.22

0.11

0.12

0.13

0.08

Philogen SpA Semi-Annual Data
	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Debt-to-Equity	Get a 7-Day Free Trial					0.12	0.12	0.13	0.18	0.08

Competitive Comparison of Philogen SpA's Debt-to-Equity

For the Biotechnology subindustry, Philogen SpA's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Philogen SpA's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Philogen SpA's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Philogen SpA's Debt-to-Equity falls into.

Save Embed

;

Save Embed

;

Philogen SpA Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Philogen SpA's Debt to Equity Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.034	+	10.473)	/	138.657
	=	0.08

Philogen SpA's Debt to Equity Ratio for the quarter that ended in Dec. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.034	+	10.473)	/	138.657
	=	0.08

Philogen SpA (STU:78Q) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Philogen SpA Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Philogen SpA's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Philogen SpA Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Philogen SpA (STU:78Q) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

PHIL:Italy 78Q:Germany

Address

Piazza La Lizza No. 7, Siena, ITA, 53100

Website

https://www.philogen.com

Philogen SpA is a biotechnology company. The company develops biotech products for the imaging and therapy of life-threatening diseases. The company's focus is predominantly related to oncology drug development, although the company has also brought products for the treatment of chronic inflammatory diseases to the clinic. Its pipeline products include Nidlegy; Fibromun; Darleukin; Dodekin; Dekavil and others. Geographically, the company operates in the European Union, Switzerland, and the United States of America.

Philogen SpA Headlines

No Headlines